Citation Impact
Citing Papers
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
2015
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials
2015
Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients
2015
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
fastp: an ultra-fast all-in-one FASTQ preprocessor
2018 Standout
Infrared molecular fingerprinting of blood-based liquid biopsies for the detection of cancer
2021 StandoutNobel
Lung cancer statistics, 2023
2024
ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study
2016
Breast cancer
2019 Standout
A comparison of deep learning performance against health-care professionals in detecting diseases from medical imaging: a systematic review and meta-analysis
2019 Standout
Clinical-grade computational pathology using weakly supervised deep learning on whole slide images
2019 Standout
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients
2015
Breast-cancer detection using blood-based infrared molecular fingerprints
2021 StandoutNobel
Cancer statistics, 2024
2024 Standout
Cancer Statistics, 2021
2021 Standout
A view on drug resistance in cancer
2019 StandoutNature
Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non–small-cell lung cancer in the USA
2019
Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer
2013
Osimertinib: First Global Approval
2016
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
2015
MicroRNA-218 functions as a tumor suppressor in lung cancer by targeting IL-6/STAT3 and negatively correlates with poor prognosis
2017
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Oncogenic BRAF Regulates Oxidative Metabolism via PGC1α and MITF
2013
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Integrating liquid biopsies into the management of cancer
2017
Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations
2016
Applications of CRISPR-Cas Enzymes in Cancer Therapeutics and Detection
2018 StandoutNobel
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
Prognostic and predictive biomarkers in lung cancer. A review
2014
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
2017
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC)
2016
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
2015
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
High-performance medicine: the convergence of human and artificial intelligence
2018 Standout
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
2015
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
Deep learning in histopathology: the path to the clinic
2021 Standout
Liquid biopsy
2015
Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection
2017
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA
2017
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction
2015
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
2017
Gastric cancer
2020 Standout
Applications of machine learning in drug discovery and development
2019 Standout
Integrated digital error suppression for improved detection of circulating tumor DNA
2016
Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view
2017 Standout
Digital pathology and artificial intelligence
2019 Standout
Targeting the RAS pathway in melanoma
2011
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Tumour heterogeneity and resistance to cancer therapies
2017 Standout
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma
2017
Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer
2015
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses
2017
Peptidic degron for IMiD-induced degradation of heterologous proteins
2019 StandoutNobel
Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer
2016
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
2016
Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer
2016
Artificial intelligence in cancer imaging: Clinical challenges and applications
2019 Standout
Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer
2016
The Versatile Role of microRNA-30a in Human Cancer
2017 Standout
Frequent detection of BRAFV 600E mutations in histiocytic and dendritic cell neoplasms
2014
UV Radiation and the Skin
2013 Standout
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
2015
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
2018
Works of Simon Dearden being referenced
Identification of a Subset of Human Non–Small Cell Lung Cancer Patients with High PI3Kβ and Low PTEN Expression, More Prevalent in Squamous Cell Carcinoma
2013
EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples
2012
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
2013
Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study
2009
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
2015
Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status
2014
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).
2015
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of technologies to support the clinical development of AZD9291.
2014
Levels of Egfr T790M in Plasma Dna As a Predictive Biomarker for Response to Azd9291, a Mutant-Selective Egfr Kinase Inhibitor
2014